Inactive Instrument

Standard BioTools Inc.

SLGC

US83444K1051

Biotechnology & Medical Research

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

December 31, 2023 at 07:10 pm

On December 31, 2023, Boston Millennia Partners announced that it intends to vote against the SomaLogic planned merger with Standard BioTools Inc.

Latest news about Standard BioTools Inc.

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	01-10	CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	01-10	CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	01-08	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Standard BioTools Says Merger With SomaLogic Completed	01-05	MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	01-05	MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	01-05	CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	01-04	CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders	01-04	CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery	01-03	CI
Madryn Asset Provides Information to the Shareholders	01-03	CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-7.44%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+27.60%	31.24B
ICON PUBLIC LIMITED COMPANY	+13.62%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+45.58%	14.06B
MEDPACE HOLDINGS, INC.	+39.99%	13.12B
BIO-TECHNE CORPORATION	-6.64%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.92%	10.68B

Other Biotechnology & Medical Research

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Latest news about Standard BioTools Inc.

Chart Standard BioTools Inc.

Company Profile

Sector Other Biotechnology & Medical Research